Business Wire

VALAMIS

Share
Valamis Announces Acquisition of The Working Manager to Redefine Internal Career Development

Valamis , the global leader in digital learning technologies and workforce development, has announced the acquisition of The Working Manager (TWM), a leader in organisational performance and career mobility technology. Valamis and TWM have entered into a definitive agreement to join together and unify technologies and in-house consulting services to offer businesses an end-to-end employee experience that helps employees develop and find career opportunities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005023/en/

Valamis Learning Solution and TWM’s CareerBurst career platform and learning platform technologies will bring Executives, Human Resources, Learning & Development, and Talent professionals a technology and consulting solution to develop and retain employees for organisational performance. Valamis and TWM will be able to help over 3 million learners and serve a diverse global client base.

“The Working Manager’s technology, proven record of customer satisfaction, and most importantly their people, are a complete fit with Valamis’ longstanding values. With TWM’s internal career development platform, LMS, and LXP, we will enhance our current learning solutions for our customers and future customers. Together, our technology, partnership approach, and authenticity will give the market a solution that puts people first and helps customers every step of the way succeed with their business initiatives”, explained Jussi Hurskainen, CEO, Valamis.

After a long period of remote work for many employees across the world at the onset of the pandemic, many businesses have begun outlining their ‘return to the office’ plans, which has ushered in what NPR is calling the ‘Great Resignation’, as more workers in the U.S. are quitting their jobs than at any time in at least two decades. According to a LinkedIn report , 94% of employees would stay at a company longer if it invested in their careers. The acquisition and combined products and services of Valamis and TWM will provide an opportunity for employers to reduce the high cost of employee turnover and labour shortages by upskilling their employees and improving career mobility.

“At TWM our accounts managers are all former heads of L&D, we understand first-hand many of the challenges that our customers are facing. That helps us develop our software in line with those requirements but also gives us an understanding of the partnership that is required to address the rapidly changing needs of businesses. Valamis has a similar approach and company culture that will empower businesses across the U.K. and globally to build greater employee loyalty and, in the end – stronger businesses”, said Phil Purver, CEO, TWM.

About Valamis

Valamis is an international technology company specialising in cloud-based digital learning solutions that empower millions of learners, companies, and societies to solve their challenges with transformative learning experiences. Valamis’ end-to-end learning solution includes Valamis’ LXP, LMS, LRS, Content Authoring Lesson Studio, eCommerce, and extensive integrations. Valamis creates long-term value for businesses and their people by being a strategic partner in learning while providing technology and consultancy services in design, data science, technology, corporate performance, and digital learning. Founded in 2003, Valamis is headquartered in Finland and maintains offices in countries around the world.

Learn more about Valamis: Website | YouTube | LinkedIn | Twitter

About TWM

TWM is the most reputable provider of Learning Platforms for clients who have a strategic take on developing their people. Our difference is that our people are former L&D professionals. We always work closely and in partnership with clients, helping solve their problems and providing a platform that we guarantee will do what we say it will.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release

- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release

-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye